As healthcare providers and pharmaceutical companies ramp up research and development efforts, we foresee a dynamic market ...

A breakthrough in Taiwan could mean earlier diagnosis and personalized treatment for those suffering from arthritis and ...

Rheumatoid arthritis is a common disease affecting an estimated 17 million people worldwide. The disease is caused by immune cells attacking the joints and can result in pain, swelling, and damage to ...

Researchers employed analysis tools and machine learning algorithms to identify two genes linked to rheumatoid arthritis and osteoporosis that could serve as diagnostic tools and potential targets for ...

Rheumatoid arthritis is a common disease affecting an estimated 17 million people worldwide. The disease is caused by immune cells attacking the joints and can result in pain, swelling, and damage to ...

Two "key" genes have been identified by scientists linking the painful condition and the bone disease osteoporosis.

There are alternatives', but doctors urge existing patients to stay on treatment The Royal Australian College of General Practitioners (RACGP) this year updated its guidance for osteoporosis ...

A disqualifying disposition essentially turns your incentive stock option into an NSO, disqualifying them from favorable tax treatment. There is no tax liability when you exercise the options and ...

The drug, Orlynvah, has been approved to treat uncomplicated UTIs in women who have limited oral antibacterial treatment options or none at all. UTI is a common bacterial infection of the bladder ...

But there are also several treatment options available, which can help slow the breakdown of bone in your body, and even encourage the growth of new bone. We’ll take a look at these below. The most ...

Early diagnosis is critical for effective treatment and management of juvenile osteoporosis. Since a peak bone mass is reached by age 30 years, if your bone mass is affected by juvenile ...

This regimen will be compared against docetaxel in patients with advanced or metastatic NSCLC, who have experienced disease progression with front-line or maintenance ICI therapy after initial ...